FDA approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with pheochromocytoma or paraganglioma that cannot be surgically removed, have spread beyond the original tumor site and require systemic anticancer therapy.
With a growing backlog at NIH and Columbia University’s grants getting canceled over alleged antisemitism, where does that leave NCI-designated cancer centers?
